Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized, Double-blind, Placebo-controlled Clinical Study to Evaluate the Efficacy, Safety, and Immunogenicity of SARS-CoV-2 Variant (BA.4/5) mRNA Vaccine (ABO1020) in Healthy Subjects Aged 18 Years and Older Who Have Completed the Full Vaccination

NCT05636319 is registered in ClinicalTrials.gov with Suzhou Abogen Biosciences Co., Ltd. as lead sponsor.

NCT NCT05636319
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05636319 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized, Double-blind, Placebo-controlled Clinical Study to Evaluate the Efficacy, Safety, and Immunogenicity of SARS-CoV-2 Variant (BA.4/5) mRNA Vaccine (ABO1020) in Healthy Subjects Aged 18 Years and Older Who Have Completed the Full Vaccination
Lead sponsor
Suzhou Abogen Biosciences Co., Ltd.
Phase
Phase 2/3
Overall status
Unknown status
Start date
November 23, 2022
Completion date
July 31, 2024
Enrollment
14,168 (actual)
Sites
25

Conditions

As the registry lists them; a condition with its own page is linked.

covid-19